Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer

Abstract Treatment options for metastatic castration-resistant prostate cancer (CRPC) have evolved with the established benefit of the novel androgen receptor (AR)-targeted agents abiraterone and enzalutamide in the prechemotherapy setting. However, concerns regarding cross-resistance between the ta...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European urology 2015-06, Vol.67 (6), p.981-985
Hauptverfasser:	van Soest, Robert J, de Morrée, Ellen S, Kweldam, Charlotte F, de Ridder, Corrina M.A, Wiemer, Erik A.C, Mathijssen, Ron H.J, de Wit, Ronald, van Weerden, Wytske M
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Androgen receptor Animals Antineoplastic Agents - therapeutic use Cabazitaxel Castration-resistant prostate cancer Cross-resistance Disease Models, Animal Disease Progression Docetaxel Drug Resistance, Neoplasm Enzalutamide Humans Ki-67 Antigen - metabolism Male Mice Middle Aged Phenylthiohydantoin - analogs & derivatives Phenylthiohydantoin - therapeutic use Prostate-Specific Antigen - blood Prostatic Neoplasms, Castration-Resistant - blood Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - metabolism Prostatic Neoplasms, Castration-Resistant - pathology Receptors, Androgen - metabolism Taxanes Taxoids - therapeutic use Treatment Outcome Urology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!